摘要
目的:分析血清肿瘤坏死因子受体相关因子3(TRAF3)和卵泡抑素样蛋白1(FSTL1)水平检测对系统性红斑狼疮患者吗替麦考酚酯治疗无效的预测价值。方法:选择系统性红斑狼疮患者58例为研究对象,采用吗替麦考酚酯治疗,根据治疗效果分为有效组(45例)和无效组(13例)。检测血清TRAF3、FSTL1水平,分析TRAF3、FSTL1与系统性红斑狼疮患者吗替麦考酚酯治疗效果的关系,以及血清TRAF3、FSTL1对系统性红斑狼疮患者吗替麦考酚酯治疗无效的预测价值。结果:系统性红斑狼疮患者经吗替麦考酚酯治疗后,血清TRAF3、FSTL1水平降低(均P<0.05)。与无效组比较,有效组血清TRAF3、FSTL1水平降低(均P<0.05)。Logistic回归分析结果显示,TRAF3、FSTL1是系统性红斑狼疮患者吗替麦考酚酯治疗效果的影响因素(均P<0.05)。ROC曲线分析显示,血清TRAF3、FSTL1对系统性红斑狼疮患者吗替麦考酚酯治疗无效具有一定的预测价值,且联合检测预测价值更高(均P<0.05)。结论:血清TRAF3、FSTL1高表达与系统性红斑狼疮患者吗替麦考酚酯治疗无效相关,两者联合检测能提升系统性红斑狼疮患者治疗无效风险的预测价值。
Objective:To analyze the predictive value of serum tumor necrosis factor receptor-associated factor 3(TRAF3)and follistatin-like protein 1(FSTL1)levels for failure to respond to mycophenolate mofetil in patients with systemic lupus erythematosus(SLE).Methods:A total of 58 patients with SLE were selected as the study subjects,and were treated with mycophenolate mofetil.According to the treatment effect,they were divided into effective group(45 cases)and ineffective group(13 cases).The serum levels of TRAF3 and FSTL1 were detected,and the relationship between TRAF3,FSTL1 and the efficacy of mycophenolate mofetil in patients with SLE was analyzed.The predictive value of serum TRAF3 and FSTL1 for failure to respond to mycophenolate mofetil in patients with SLE was analyzed.Results:The levels of TRAF3 and FSTL1 were decreased in SLE patients after mycophenolate mofetil treatment(both P<0.05).Compared with the ineffective group,the serum levels of TRAF3 and FSTL1 in the effective group were decreased(all P<0.05).Logistic regression analysis showed that TRAF3 and FSTL1 were the influencing factors of the therapeutic effect of mycophenolate mofetil in SLE patients(all P<0.05).ROC curve analysis showed that serum TRAF3 and FSTL1 had a certain predictive value for the failure of mycophenolate mofetil treatment in SLE patients,and the predictive value of combined detection was higher(all P<0.05).Conclusion:The high expression of TRAF3 and FSTL1 is associated with no response to mycophenolate mofetil treatment in SLE patients,and the combined detection of TRAF3 and FSTL1 can improve the predictive value of no response to mycophenolate mofetil treatment in SLE patients.Overexpression of serum TRAF 3 and FSTL 1 is associated with ineffective treatment with malcocohenol lipid in patients with systemic lupus erythematosus and can be used as a key biological indicator to predict therapeutic failure in patients with systemic lupus erythematosus.
作者
李丽
蒋芙蓉
赵丽英
方先英
LI Li;JIANG Furong;ZHAO Liying;FANG Xianying(Department of Endocrinology,Santai Hospital Affiliated to North Sichuan Medical College,Mianyang 621100,China)
出处
《陕西医学杂志》
CAS
2024年第9期1254-1258,共5页
Shaanxi Medical Journal
基金
四川省中医药管理局科学技术研究专项课题(2023MS239)。
关键词
系统性红斑狼疮
肿瘤坏死因子受体相关因子3
卵泡抑素样蛋白1
吗替麦考酚酯
预测价值
Systemic lupus erythematosus
Tumor necrosis factor receptor-associated factor 3
Follistatin-like protein 1
Mycophenolate mofetil
Predictive value
